Navidea Reports Second Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Navidea Biopharma (NAVB) Misses Q2 EPS by 2c
July 30, 2015 7:36 AM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.18 million.
Specific events and milestones achieved since the beginning of the second quarter include the following:
Commercial
Achieved sequential quarter-on-quarter Lymphoseek revenue growth and continued improvement in key performance indicators;Fully deployed a Lymphoseek-dedicated field force mid-second quarter;Exercised pricing... More